With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33100-27-5,1,4,7,10,13-Pentaoxacyclopentadecane,as a common compound, the synthetic route is as follows.
Sodium hydride (60percent dispersion in mineral oil, 0.14 g) was added portionwise to a stirred solution of a portion (0.87 g) of the 3-hydroxypyrrolidine so obtained and 1,4,7,10,13-pentaoxacyclopentadecane (hereinafter 15-crown-5, 0.05 g) in DMF (10 ml). The mixture was stirred at ambient temperature for 15 minutes. A solution of methyl 4-toluenesulphonate (0-56 g) in THF (2 ml) was added dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was partitioned between diethyl ether and water. The organic phase was dried (Na2 SO4) and evaporated. The residue was purified by column chromatography using increasingly polar mixtures of hexane and ethyl acetate as eluent. There was thus obtained 1-benzyl-3-(3,5-difluorophenyl)-3-methoxypyrrolidine (0.82 g, 90percent).
33100-27-5 1,4,7,10,13-Pentaoxacyclopentadecane 36336, achiral-catalyst compound, is more and more widely used in various.
Reference£º
Patent; Zeneca Limited; Zeneca Pharma S.A.; US5420298; (1995); A;,
Chiral Catalysts
Chiral catalysts – SlideShare